The global cancer immunotherapy drug discovery outsourcingmarket is project worth $1.8 Billion in 2026 and the market is projected to showcase 14.0% CAGR during the forecast period.

The market is driven by increasing cancer patients and surging awareness about developments and improvement in cancer immunotherapy.

Report coverage

Market	Cancer Immunotherapy Drug Discovery Outsourcing Market
Analysis Period	2015 - 2026
Base Year	2017
Forecast Data	2018 - 2026
Segments Covered	By Drug Type, By Service Type, By Cancer Type and By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Aquila BioMedical,Crown Bioscience, Inc.,Molecular Imaging, Inc.,Explicyte,Horizon Discovery Group PLC,STC Biologics,Promega Corporation,Personalis, Inc.,HD Biosciences Co.,DiscoverX Corporation,Genscript Biotech Corporation,BPS Bioscience, Inc.,ImmunXperts SA, andCelentyx Ltd.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope	10 hrs of free customization and expert consultation

 

Market Dynamics

Increase in occurrence of cancer disease and increasing mortality associated with cancer are the key reasons for the growth of the cancer immunotherapy drug discovery outsourcing market. Furthermore, supportive government regulation for healthcare sector is optimistically impacting the development of the market and is anticipated to drive the development during the forecast period.

Increasing number of cancer patients across the world drive the demand for better cancer treatment and diagnostics services globally during the forecast period. Also, Pharmaceutical businesses are concentrating on immunotherapies subsequently they are a potential treatment alternative for cancer due to their capability to shrink the risk of post chemotherapy tumor reoccurrence.

Furthermore, favourable tax credit permits pharmaceutical businesses to properly plan their global projects with a reputed CRO, which will help in them in growing their business and avoiding taxation related problems. This factor also contribute in the growth of the market.

Market Insights

The global cancer immunotherapy drug discovery outsourcingmarket is anticipated to account the substantial growth in the coming years, attributed to increasing alertness and awareness about developments in cancer immunotherapy paired with growing investments by pharmaceutical businesses in outsourcing and subcontracting is anticipated to boost in the growth of thecancer immunotherapy drug discovery outsourcing market.

Market Classification

The global cancer immunotherapy drug discovery outsourcing market is segmented into four major segment named drug type, service type, cancer type, and region. On the basis of drug type the cancer immunotherapy drug discovery outsourcing market is segmented intomonoclonal antibodies, immunomodulators, oncolytic viral therapies and cancer vaccines, and others. On the basis of the service type the global cancer immunotherapy drug discovery outsourcing market is segmented into target identification and validation, lead screening and characterization and cell based assays.On the basis of cancer type, the cancer immunotherapy drug discovery outsourcing market is segmented into lung, breast, colorectal, melanoma, prostate, head and neck, ovarian and pancreatic. On the basis of region the global Cancer Immunotherapy Drug Discovery Outsourcing market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Regional Insights

In 2018, North America accounts largest revenue share and the region is anticipated to continue its dominance over the forecast period as the region has domicile of big pharmaceutical giants. Other reason for the growth of the North America cancer immunotherapy drug discovery outsourcing market are high per capita healthcare expenditure, and increasing awareness about the canner treatment and diagnostic system.

Europe is anticipated to be the second fastest-developing market for cancer immunotherapy drug discovery outsourcing. Increased incidence of cancer diseases and occurrence of a huge target population base are the crucial factors growing demand for cancer immunotherapy drug discovery outsourcingin the region.

Market Participants

The major players associated with the cancer immunotherapy drug discovery outsourcing market Aquila BioMedical,Crown Bioscience, Inc.,Molecular Imaging, Inc.,Explicyte,Horizon Discovery Group PLC,STC Biologics,Promega Corporation,Personalis, Inc.,HD Biosciences Co.,DiscoverX Corporation,Genscript Biotech Corporation,BPS Bioscience, Inc.,ImmunXperts SA, andCelentyx Ltd.

Market Segmentation

Market ByDrug type

• Monoclonal Antibodies
• Immunomodulators
• Oncolytic Viral Therapies and Cancer Vaccines
• Others

Market ByCancer type

• Target Identification and Validation
• Lead Screening and Characterization
• Cell Based Assays

Market ByService type

• HealtLung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head and Neck
• Ovarian
• Pancreatic

Market By Geography

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • UK
  • Germany
  • France
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America

• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA

 

TABLE OF CONTENT